• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Why Immunovant (IMVT) Is Up 15.1% And What's Next

    Simply Wall St·11/10/2026 14:22:16
    Listen to the news
    • Immunovant reported second quarter net loss of US$97.25 million and basic loss per share of US$0.47, while releasing positive topline data for IMVT-1402 in difficult to treat rheumatoid arthritis and early commercial revenue figures for LISRAYA.
    • The company also filed a US$150 million at the market equity program and a broad shelf registration, highlighting the funding tools it may use to support further IMVT-1402 development and commercial expansion around LISRAYA.
    • Now the focus turns to how Immunovant's investment narrative could shift in light of IMVT-1402's rheumatoid arthritis data and early LISRAYA launch traction.

    Scan how Immunovant's latest rheumatoid arthritis data and funding plans compare with other late stage biotech opportunities on our hand picked list of 19 high quality undiscovered gems

    Immunovant Investment Narrative Recap

    To own Immunovant, you need to believe IMVT-1402 can convert its rheumatoid arthritis and Graves' programs into a real autoimmune franchise while LISRAYA matures from launch to a repeatable revenue stream. The latest quarter still showed a net loss of US$97.25 million, so the business remains firmly in investment mode rather than self funded.

    The analyst consensus Narrative on Simply Wall St had already flagged IMVT-1402 data and trial timing as central. Positive difficult-to-treat rheumatoid arthritis results support that near term catalyst, while discontinuing further Sjögren's work and keeping losses sizeable keeps trial execution and cash discipline as the biggest risks for now.

    The US$150 million at-the-market equity program is the announcement that matters most here. It sits next to the broad shelf registration and gives Immunovant flexibility to raise capital in smaller increments as IMVT-1402 progresses and as LISRAYA commercial data come through, rather than relying on a single large issuance.

    For you as a shareholder, this tool cuts both ways. It can help sustain trials and launches without abrupt funding gaps, which supports the IMVT-1402 rheumatoid arthritis and Graves' catalysts, but frequent use could add to the dilution that the analyst consensus Narrative on Simply Wall St already factors in as a key risk.

    Immunovant's narrative projects US$559.3 million revenue and US$101.9 million earnings by 2029. This would represent a shift from no revenue today, alongside an earnings improvement of about US$640.1 million from current earnings of a US$538.2 million loss.

    Uncover why Immunovant's fair value indicates a 37% potential upside to its current price that could narrow quickly.

    NasdaqGS:IMVT 1-Year Stock Price Chart
    NasdaqGS:IMVT 1-Year Stock Price Chart

    Exploring Other Perspectives

    One alternate view on Immunovant focuses squarely on revenue potential. While the baseline narrative works off forecasts of US$559.3 million by 2029, the most cautious analysts were only penciling in about US$1.4 million and earnings of roughly US$206.6 thousand. That is a far more pessimistic story. These estimates all pre date the rheumatoid arthritis data and LISRAYA launch, so you may want to compare several viewpoints and decide which assumptions feel closer to your own.

    Explore another Immunovant fair value estimate, including one that suggests it could be worth just $48.07.

    Decide For Yourself

    Don't just follow the ticker; dig into the data and build a conviction that's truly your own.

    Looking For More Investment Ideas Beyond Immunovant?

    Once you have a view on Immunovant, it can help to set it against a wider watchlist. That way you see how its risk, balance sheet and potential reward stack up beside very different types of opportunities surfaced by the Simply Wall St Screener.